Surgery Partners, Inc. 10-Q

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the condensed consolidated financial statements and related notes included elsewhere in this report and our 2024 Annual Report on Form 10-K. Unless the context otherwise indicates, the terms "Surgery Partners," "we," "us," "our" or the "Company," as used herein, refer to Surgery Partners, Inc. and its subsidiaries, and the term "affiliates" means direct and indirect subsidiaries of Surgery Partners, Inc. and partnerships and joint ventures in which such subsidiaries are partners. The terms "facilities" or "hospitals" refer to entities owned and operated by affiliates of Surgery Partners, Inc. and the term "employees" refers to employees of affiliates of Surgery Partners, Inc. Cautionary Note Regarding Forward-Looking Statements This report contains forward-looking statements, which are based on our current expectations, estimates and assumptions about future events. All statements other than statements of current or historical fact contained in this report are forward-looking statements. These statements include, but are not limited to, statements regarding our future financial position, business strategy, budgets, effective tax rate, projected costs and plans and objectives of management for future operations. The words "projections," "believe," "continue," "drive," "estimate," "expect," "intend," "may," "plan," "will," "could," "would" and similar expressions are generally intended to identify forward-looking statements. By their nature, forward-looking statements involve risks, uncertainties and other factors that may cause actual results to differ from the expectations expressed in the statements. Many of these factors are beyond our ability to control or predict. These factors include, without limitation, reductions in payments from government health care programs and private insurance payors, such as health maintenance organizations, preferred provider organizations, and other managed care organizations and employers; our ability to contract with private insurance payors; changes in our payor mix or surgical case mix; failure to maintain or develop relationships with physicians on beneficial or favorable terms, or at all; the impact of payor controls designed to reduce the number of surgical procedures; our efforts to integrate operations of acquired businesses and surgical facilities, attract new physician partners, or acquire additional surgical facilities; supply chain issues, including shortages or quality control issues with surgery-related products, equipment and medical supplies; competition for physicians, nurses, strategic relationships, acquisitions and managed care contracts; our ability to attract and retain qualified health care professionals; our ability to enforce non-compete restrictions against our physicians; our ability to manage material liabilities whether known or unknown incurred as a result of acquiring surgical facilities; the impact of current and future legislation and other health care public policy changes, and the effect of that legislation and other regulatory actions on our business; our ability to comply with current health care laws and regulations; the outcome of legal and regulatory proceedings that have been or may be brought against us; the impact of cybersecurity attacks or intrusions; changes in the regulatory, economic and other conditions of the states where our surgical facilities are located; our indebtedness; the social and economic impact of a pandemic, epidemic or outbreak of a contagious disease on our business; and the risks and uncertainties set forth under the heading "Risk Factors" in our 2024 Annual Report on Form 10-K and discussed from time to time in our reports filed with the SEC. Considering these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur, and actual results could differ materially from those anticipated or implied in the forward-looking statements. When you consider these forward-looking statements, you should keep in mind these risk factors and other cautionary statements in this report. These forward-looking statements speak only as of the date made. Other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events or otherwise. Executive Overview As of June 30, 2025, we owned or operated, primarily in partnership with physicians, a portfolio of 162 surgical facilities comprised of 143 ASCs and 19 surgical hospitals across 30 states. We owned a majority interest in 83 of the surgical facilities and consolidated 115 of these facilities for financial reporting purposes. Total revenues for the second quarter of 2025 increased 8.3% to $826.2 million from $762.1 million for the second quarter of 2024. The increase in revenues was attributable to same-facility revenue growth and the net impact from acquisitions and divestitures completed during the last twelve months ended June 30, 2025. Days adjusted same-facility revenues for the second quarter of 2025 increased 5.1% from the second quarter of 2024, with a 1.6% increase in revenue per case and a 3.4% increase in same-facility cases. Additionally, for the second quarter of 2025, net loss attributable to Surgery Partners, Inc. was $2.5 million compared to $15.5 million for the 2024 period. For the second quarter of 2025, Adjusted EBITDA increased 9.0% to $129.0 million compared to $118.3 million for the same period in 2024. The increase in Adjusted EBITDA was primarily attributable to revenue growth, continued cost management initiatives and acquisitions completed since the prior year period. A reconciliation of non-GAAP financial measures appears below under the heading "Certain Non-GAAP Measures." We continue to focus on improving our same-facility performance, selectively acquiring established facilities, developing new facilities and pursuing other portfolio management initiatives. During the second quarter of 2025, we acquired a controlling interest in four surgical facilities and two physician practice for aggregate cash consideration of $48.0 million, net of cash acquired. We had cash and cash equivalents of $250.1 million and $394.9 million of borrowing capacity under the Revolver as of June 30, 2025. 18 Table of Contents Recent Legislation On July 4, 2025, Congress passed the One Big Beautiful Bill Act (the “OBBBA”), which introduced significant changes to federally funded healthcare programs, including Medicaid, Medicare, and the Affordable Care Act. While such changes are projected to reduce overall healthcare spending and increase regulatory burdens in certain jurisdictions in which the Company operates, they are not expected to materially impact the Company's financial statements. The OBBBA also makes permanent key elements of the Tax Cuts and Jobs Act including, among others, 100% bonus depreciation and the business interest expense limitations. The Company is currently assessing the implications of these tax law changes. Since the OBBBA Act was enacted subsequent to the balance sheet date, the Company’s tax provision for the three and six months ended June 30, 2025, does not incorporate the effects of these tax law changes. Revenues Our revenues consist of patient service revenues and other service revenues. Patient service revenues consist of revenue from our Surgical Facilities reportable segment. Specifically, patient service revenues include fees for surgical or diagnostic procedures performed at surgical facilities that we consolidate for financial reporting purposes, as well as for patient visits to our physician practices, anesthesia services, pharmacy services and diagnostic screens ordered by our physicians. Other service revenues include management and administrative service fees derived from our non-consolidated facilities that we account for under the equity method, management of surgical facilities and physician practices in which we do not own an interest, management services we provide to physician practices for which we are not required to provide capital or additional assets and other non-patient services. The following table summarizes revenues by service type as a percentage of total revenues: Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Patient service revenues: Patient service revenues 97.3 % 98.1 % 97.5 % 98.3 % Other service revenues 2.7 % 1.9 % 2.5 % 1.7 % Total revenues 100.0 % 100.0 % 100.0 % 100.0 % Payor Mix The following table sets forth by type of payor the percentage of our patient service revenues generated at the surgical facilities that we consolidate for financial reporting purposes: Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Private insurance payors 51.8 % 53.2 % 52.6 % 52.2 % Government payors 43.3 % 41.5 % 42.5 % 42.2 % Self-pay payors 2.7 % 2.8 % 2.7 % 2.8 % Other payors (1) 2.2 % 2.5 % 2.2 % 2.8 % Total 100.0 % 100.0 % 100.0 % 100.0 % (1) Comprised of automobile liability, letters of protection and other payor types. Surgical Case Mix We primarily operate multi-specialty surgical facilities where physicians perform a variety of procedures in various specialties. We believe this diversification helps to protect us from adverse pricing and utilization trends in any individual procedure type and results in greater consistency in our case volume. 19 Table of Contents The following table sets forth the percentage of cases in each specialty performed at the surgical facilities that we consolidate for financial reporting purposes for the periods indicated: Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Orthopedics and pain management 39.8 % 39.9 % 40.2 % 40.0 % Ophthalmology 22.2 % 23.4 % 22.1 % 23.4 % Gastrointestinal 24.8 % 22.6 % 24.6 % 22.3 % General surgery 1.8 % 2.3 % 2.0 % 2.3 % Other 11.4 % 11.8 % 11.1 % 12.0 % Total 100.0 % 100.0 % 100.0 % 100.0 % Critical Accounting Policies A summary of significant accounting policies is disclosed in our 2024 Annual Report on Form 10-K under the caption “Critical Accounting Policies” in the Management’s Discussion and Analysis of Financial Condition and Results of Operations section. There have been no material changes in the nature of our critical accounting policies or the application of those policies since December 31, 2024. Results of Operations Comparison of Operating Results for the Three Months Ended June 30, 2025 to the Three Months Ended June 30, 2024 The following tables summarize certain results from the condensed consolidated statements of operations for the periods indicated (in millions): Three Months Ended June 30, 2025 2024 Revenues $ 826.2 $ 762.1 Operating expenses: Cost of revenues 630.6 582.9 General and administrative expenses 36.1 40.3 Depreciation and amortization 40.3 34.8 Transaction and integration costs 18.1 19.3 Net (gain) loss on disposals, consolidations and deconsolidations (3.0) 5.3 Equity in earnings of unconsolidated affiliates (5.5) (4.4) Litigation settlements — 0.5 Loss on debt extinguishment — 5.1 Other income, net (2.1) (6.5) 714.5 677.3 Operating income 111.7 84.8 Interest expense, net (67.9) (51.5) Income before income taxes 43.8 33.3 Income tax benefit (expense) 1.1 (4.9) Net income 44.9 28.4 Less: Net income attributable to non-controlling interests (47.4) (43.9) Net loss attributable to Surgery Partners, Inc. $ (2.5) $ (15.5) 20 Table of Contents Revenues. The following table sets forth patient service revenues (in millions): Three Months Ended June 30, 2025 2024 Patient service revenues $ 804.2 $ 748.1 Other service revenues 22.0 14.0 Total revenues $ 826.2 $ 762.1 Patient service revenues increased 7.5% to $804.2 million for the three months ended June 30, 2025 compared to $748.1 million for the three months ended June 30, 2024. The increase was primarily driven by a 5.1% increase in days adjusted same-facility revenues and the net impact from acquisitions and divestitures completed during the twelve months ended June 30, 2025. The increase in days adjusted same-facility revenues was attributable to a 3.4% increase in same-facility case volumes and a 1.6% increase in same-facility revenue per case. Cost of Revenues. Cost of revenues was $630.6 million for the three months ended June 30, 2025 compared to $582.9 million for the three months ended June 30, 2024. The increase was primarily driven by an increase in case volume and the performance of high acuity procedures as well as acquisitions completed during the twelve months ended June 30, 2025. As a percentage of revenues, cost of revenues was 76.3% and 76.5% for the three months ended June 30, 2025 and 2024, respectively. General and Administrative Expenses. General and administrative expenses were $36.1 million and $40.3 million for the three months ended June 30, 2025 and 2024, respectively. As a percentage of revenues, general and administrative expenses were 4.4% and 5.3% for the three months ended June 30, 2025 and 2024, respectively. Depreciation and Amortization. Depreciation and amortization expenses were $40.3 million and $34.8 million for the three months ended June 30, 2025 and 2024, respectively. As a percentage of revenues, depreciation and amortization expenses were 4.9% and 4.6% for the three months ended June 30, 2025 and 2024, respectively. Transaction and Integration Costs. The Company incurred $18.1 million of transaction and integration costs for the three months ended June 30, 2025 compared to $19.3 million for the three months ended June 30, 2024. The costs for both periods primarily related to ongoing development initiatives and the integration of acquisitions. The decrease was primarily driven by reduced transaction and integration costs related to acquisitions and divested facilities, partially offset by an increase in severance, IT implementation, and revenue cycle standardization costs. Net (Gain) Loss on Disposals, Consolidations and Deconsolidations. The net loss on disposals, consolidations and deconsolidations for the three months ended June 30, 2025 and 2024 includes activity discussed in Note 2. "Acquisitions, Disposals and Deconsolidations" of the accompanying notes to the condensed consolidated financial statements. The remaining net loss in both periods was primarily attributable to sales and disposals of other assets. Interest Expense, Net. Interest expense, net was $67.9 million for the three months ended June 30, 2025 compared to $51.5 million for the three months ended June 30, 2024. As a percentage of revenues, interest expense, net was 8.2% and 6.8% for the three months ended June 30, 2025 and 2024, respectively. The increase was primarily driven by financing activities in 2024 related to the senior unsecured notes, increased borrowings on the Revolver and the maturity of certain interest rate swaps in the first quarter of 2025. Income Tax Benefit (Expense) . Income tax benefit was $1.1 million for the three months ended June 30, 2025 compared to income tax expense of $4.9 million for the three months ended June 30, 2024. The effective tax rate was (2.5)% and 14.7% for the three months ended June 30, 2025 and 2024, respectively. See Note 7. "Income Taxes" for additional information related to the Company's effective tax rates for the three months ended June 30, 2025 and 2024, including why these rates differed from the U.S. federal statutory rate of 21%. Net Income Attributable to Non-Controlling Interests. As a percentage of revenues, net income attributable to non-controlling interests was 5.7% and 5.8% for the three months ended June 30, 2025 and 2024, respectively. 21 Table of Contents Comparison of Operating Results for the Six Months Ended June 30, 2025 to the Six Months Ended June 30, 2024 The following tables summarize certain results from the statements of operations for the periods indicated (dollars in millions): Six Months Ended June 30, 2025 2024 Revenues $ 1,602.2 $ 1,479.5 Operating expenses: Cost of revenues 1,244.7 1,145.0 General and administrative expenses 72.1 73.5 Depreciation and amortization 76.6 68.5 Transaction and integration costs 42.8 36.7 Net loss on disposals, consolidations and deconsolidations 3.4 6.8 Equity in earnings of unconsolidated affiliates (11.1) (7.1) Litigation settlements 2.2 (1.3) Loss on debt extinguishment — 5.1 Other income, net (2.1) (8.5) 1,428.6 1,318.7 Operating income 173.6 160.8 Interest expense, net (130.1) (98.8) Income before income taxes 43.5 62.0 Income tax benefit (expense) 1.1 (9.3) Net income 44.6 52.7 Less: Net income attributable to non-controlling interests (84.8) (80.6) Net loss attributable to Surgery Partners, Inc. $ (40.2) $ (27.9) Revenues. The following table sets forth patient service revenues (in millions): Six Months Ended June 30, 2025 2024 Patient service revenues $ 1,562.6 $ 1,453.4 Other service revenues 39.6 26.1 Total revenues $ 1,602.2 $ 1,479.5 Patient service revenues increased 7.5% to $1.6 billion for the six months ended June 30, 2025 compared to $1.5 billion for the six months ended June 30, 2024. The increase was primarily driven by an 5.1% increase in days adjusted same-facility revenues and the net impact from acquisitions and divestitures completed during the twelve months ended June 30, 2025 . The increase in days adjusted same-facility revenues was attributable to a 4.7% increase in same-facility case volumes and a 0.4% increase in same-facility revenue per case. Cost of Revenues. Cost of revenues was $1.2 billion for the six months ended June 30, 2025 compared to $1.1 billion for the six months ended June 30, 2024. The increase was primarily driven by an increase in case volume and the performance of high acuity procedures as well as acquisitions completed during the twelve months ended June 30, 2025 . As a percentage of revenues, cost of revenues was 77.7% and 77.4% for the six months ended June 30, 2025 and 2024, respectively. General and Administrative Expenses. General and administrative expenses were $72.1 million and $73.5 million for the six months ended June 30, 2025 and 2024, respectively. As a percentage of revenues, general and administrative expenses were 4.5% and 5.0% for the six months ended June 30, 2025 and 2024, respectively. Depreciation and Amortization. Depreciation and amortization expenses were $76.6 million and $68.5 million for the six months ended June 30, 2025 and 2024, respectively. As a percentage of revenues, depreciation and amortization expenses were 4.8% and 4.6% for the six months ended June 30, 2025 and 2024, respectively. Transaction and Integration Costs. The Company incurred $42.8 million of transaction and integration costs for the six months ended June 30, 2025 compared to $36.7 million for the six months ended June 30, 2024. The costs for both periods primarily related to ongoing development initiatives and the integration of acquisitions. The increase was primarily driven by an increase in severance, IT implementation, and revenue cycle standardization costs, partially offset by reduced transaction and integration costs related to acquisitions and divested facilities. 22 Table of Contents Net Loss on Disposals, Consolidations and Deconsolidations. The net loss on disposals, consolidations and deconsolidations for the six months ended June 30, 2025 and 2024 includes activity discussed in Note 2. "Acquisitions, Disposals and Deconsolidations" of the accompanying notes to the condensed consolidated financial statements. The remaining net loss in both periods was primarily attributable to sales and disposals of other assets. Interest Expense, Net. Interest expense, net was $130.1 million for the six months ended June 30, 2025 compared to $98.8 million for the six months ended June 30, 2024. As a percentage of revenues, interest expense, net was 8.1% and 6.7% for the six months ended June 30, 2025 and 2024, respectively. The increase was primarily driven by financing activities in 2024 related to the senior unsecured notes and increased borrowings on the Revolver. Income Tax Benefit (Expense) . Income tax benefit was $1.1 million for the six months ended June 30, 2025 compared to income tax expense of $9.3 million for the six months ended June 30, 2024. The effective tax rate was (2.5)% and 15.0% for the six months ended June 30, 2025 and 2024, respectively. See Note 7. "Income Taxes" for additional information related to the Company's effective tax rates for the six months ended June 30, 2025 and 2024, including why these rates differed from the U.S. federal statutory rate of 21%. Net Income Attributable to Non-Controlling Interests. As a percentage of revenues, net income attributable to non-controlling interests was 5.3% and 5.4% for the six months ended June 30, 2025 and 2024, respectively. Liquidity and Capital Resources Cash and cash equivalents were $250.1 million at June 30, 2025 compared to $269.5 million at December 31, 2024. The primary source of our operating cash flows is the collection of accounts receivable from private insurance companies, federal and state agencies (under the Medicare and Medicaid programs) and individuals. Our cash flows provided by operating activities was $87.3 million for the six months ended June 30, 2025 compared to $123.5 million for the six months ended June 30, 2024. The $36.2 million decrease was primarily driven by driven by higher cash interest payments and timing of changes in working capital. Net cash used in investing activities for the six months ended June 30, 2025 was $74.3 million compared to $327.2 million for the six months ended June 30, 2024. The $252.9 million decrease was primarily driven by an aggregate net decrease of $214.5 million in payments for acquisitions (net of cash acquired) and purchases of equity method investments and a $41.4 million increase in proceeds from sales of facilities. Net cash used in financing activities for the six months ended June 30, 2025 was $32.4 million compared to net cash provided of $221.3 million for the six months ended June 30, 2024. The decrease of $253.7 million was primarily driven by net proceeds from borrowings on long-term debt during the six months ended June 30, 2024 and a $35.6 million increase in distributions to non-controlling interest holders in the six months ended June 30, 2025 compared to the six months ended June 30, 2024. Capital Resources Net working capital was approximately $532.0 million at June 30, 2025 compared to $495.0 million at December 31, 2024. In addition to cash flows from operations and available cash, other sources of capital include amounts available on our Revolver as well as anticipated continued access to the capital markets. Material Cash Requirements There have been no material changes outside of the ordinary course of business to our upcoming cash obligations during the six months ended June 30, 2025 from those disclosed under “Material Cash Requirements” in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our 2024 Annual Report on Form 10-K. Summary Broad economic factors, including recent changes in interest rates, inflation and supply chain risks and market volatility, could negatively affect our payor mix, increase the relative proportion of lower margin services we provide and reduce patient volumes, as well as diminish our ability to collect outstanding receivables. Any increase in the amount or deterioration in the collectability of patient accounts receivable will adversely affect our cash flows and results of operations, requiring an increased level of working capital. If general economic conditions, including recent changes in interest rates, inflation risk and market volatility, continue to deteriorate or remain uncertain for an extended period of time, our ability to access capital could be harmed, which could negatively affect our liquidity and ability to repay our outstanding debt. Based on our current level of operations, we believe cash flows from operations, available cash, available capacity on our Revolver and continued anticipated access to capital markets, will be adequate to meet our short-term (i.e., 12 months) and long-term (beyond 12 months) liquidity needs. Certain Non-GAAP Measures Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be considered in isolation or as a substitute for net income, operating income or any other measure calculated in accordance with GAAP. The items excluded from this non- 23 Table of Contents GAAP metric are significant components in understanding and evaluating our financial performance. We believe such adjustments are appropriate, as the magnitude and frequency of such items can vary significantly and are not related to the assessment of normal operating performance. Our calculation of Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. We use Adjusted EBITDA as a measure of financial performance. Adjusted EBITDA is a key measure used by our management to assess operating performance, make business decisions and allocate resources. The following table reconciles Adjusted EBITDA to income before income taxes, the most directly comparable GAAP financial measure (in millions and unaudited): Three Months Ended June 30, Six Months Ended June 30, 2025 2024 2025 2024 Condensed Consolidated Statements of Operations Data: Income before income taxes $ 43.8 $ 33.3 $ 43.5 $ 62.0 Plus (minus): Net income attributable to non-controlling interests (47.4) (43.9) (84.8) (80.6) Interest expense, net 67.9 51.5 130.1 98.8 Depreciation and amortization 40.3 34.8 76.6 68.5 Equity-based compensation expense 6.8 15.1 14.4 20.0 Transaction and integration costs (1) 18.1 19.3 42.8 36.7 De novo start-up costs 2.1 1.5 3.7 3.0 Net loss on disposals, consolidations and deconsolidations (3.0) 5.3 3.4 6.8 Litigation settlements and other litigation costs (2) 0.4 1.1 3.2 (0.1) Loss on debt extinguishment — 5.1 — 5.1 Other — (4.8) — (4.4) Adjusted EBITDA $ 129.0 $ 118.3 232.9 215.8 (1) For the three months ended June 30, 2025, this amount includes due diligence, transaction and integration costs related to acquisitions (both completed and in the pipeline) and divested facilities (collectively “M&A costs”) of $14.1 million and other costs, including severance, IT implementation, revenue cycle standardization of $4.0 million For the three months ended June 30, 2024, this amount includes M&A costs of $16.2 million and other costs, including severance, IT implementation, revenue cycle standardization of $3.1 million. For the six months ended June 30, 2025, this amount includes M&A costs of $30.9 million and other costs, including severance, IT implementation, revenue cycle standardization of $11.9 million For the six months ended June 30, 2024, this amount includes M&A costs of $32.1 million and other costs, including severance, IT implementation, revenue cycle standardization of $4.6 million. (2) This amount includes a litigation settlement loss of $0.5 million for the three months ended June 30, 2024. This amount also includes other litigation costs of $0.4 million and $0.6 million for the three months ended June 30, 2025 and 2024, respectively. This amount includes a litigation settlement loss of $2.2 million and a gain of $1.3 million for the six months ended June 30, 2025 and 2024, respectively. This amount also includes other litigation costs of $1.0 million and $1.2 million for the six months ended June 30, 2025 and 2024, respectively. We use Credit Agreement EBITDA as a measure of liquidity and to determine our compliance under certain covenants pursuant to our Credit Agreement, as amended. Credit Agreement EBITDA is determined on a trailing twelve-month basis. We have included it because we believe that it provides investors with additional information about our ability to incur and service debt and make capital expenditures. Credit Agreement EBITDA is not a measurement of liquidity under GAAP and should not be considered in isolation or as a substitute for any other measure calculated in accordance with GAAP. The items excluded from Credit Agreement EBITDA are significant components in understanding and evaluating our liquidity. Our calculation of Credit Agreement EBITDA may not be comparable to similarly titled measures reported by other companies. When we use the term "Credit Agreement EBITDA," we are referring to Adjusted EBITDA, as defined above, further adjusted for acquisitions and synergies. These adjustments do not relate to our historical financial performance and instead relate to estimates compiled by management and calculated in conformance with the definition of "Consolidated EBITDA" used in the credit agreements governing our credit facilities. 24 Table of Contents The following table reconciles Credit Agreement EBITDA to cash flows from operating activities, the most directly comparable GAAP financial measure (in millions and unaudited): Twelve Months Ended June 30, 2025 Cash flows from operating activities $ 263.9 Plus (minus): Non-cash interest expense, net (7.4) Non-cash lease expense (39.7) Deferred income taxes (122.1) Equity in earnings of unconsolidated affiliates, net of distributions received 2.0 Changes in operating assets and liabilities, net of acquisitions and divestitures 133.3 Income tax expense 124.2 Net income attributable to non-controlling interests (184.8) Interest expense, net 233.0 Transaction and integration costs 106.2 De novo start-up costs 8.6 Litigation settlements and other litigation costs 6.4 Other 1.7 Acquisitions and synergies (1) 53.7 Credit Agreement EBITDA $ 579.0 (1) Represents impact of acquisitions as if each acquisition had occurred on July 1, 2024. Further this includes revenue and cost synergies from other business initiatives and de novo facilities and an adjustment for the effects of adopting the new lease accounting standard, as defined in the credit agreement governing the Credit Agreement, as amended.